Neurocrine execs shrug off a PhII setback for Tourette syndrome
Neurocrine was forced to concede that its lead drug – already on track at the FDA with an application for tardive dyskinesia — just flunked a Phase II trial in Tourette syndrome.
The VMAT2 inhibitor improved symptoms among the patients taking the drug, but failed to hit the primary endpoint for the change-from-baseline in the Yale Global Tic Severity Scale at week 8. The biotech, though, is keeping the hard data under wraps for now.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.